Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series.

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Immunotherapy 100%
• Monotherapy 80%
• Combination Therapy 60%
• Hepatitis 60%
• Corticosteroid 40%
• Pneumonia 40%
• Colitis 40%
• Cytotoxic T Lymphocyte Antigen 4 40%
• Immune Checkpoint Inhibitor 40%
• Endocrine Disease 40%
• Non Small Cell Lung Cancer 20%
• Morbidity 20%
• Prevalence 20%
• Clinical Trial 20%
• Complication 20%
• Steroids 20%
• Melanoma 20%
• Autoimmune Disease 20%
• Dermatitis 20%
• Renal Cell Carcinoma 20%

Immunology and Microbiology

• Immunity 100%
• Immunotherapy 100%
• Hepatitis 50%
• Health 33%
• Colitis 33%
• Pneumonitis 33%
• CTLA-4 33%
• Cells 16%
• Lung 16%
• Prevalence 16%
• Age 16%
• Length 16%
• Autoimmune Disease 16%
• Morbidity 16%
• Nomenclature 16%
• Immunosuppression 16%
• Programmed Death-Ligand 1 16%
• Carcinoma Cell 16%
• Dermatitis 16%